phic eGFP-MGMT variants confers similar resistance to TMZ. However, upon exposure to O 6 -benzylguanine (O 6 -BG), a synthetic MGMT inhibitor, the L84F and L84F/I143V/K178R variants were degraded more rapidly than WT or I143V/K178R in a proteasome-dependent manner. Despite the increased O 6 -BG-stimulated protein turnover caused by the L84F alteration, cells expressing L84F eGFP-MGMT did not exhibit altered sensitivity to the combination of O 6 -BG and TMZ compared with WT cells. In conclusion, we demonstrated that the L84F polymorphic variant has altered protein turnover without modifying sensitivity of U87MG cells to TMZ or combined TMZ and O 6 -BG. These findings may provide a clue to determining the clinical significance of MGMT coding-region polymorphisms. NeuroOncology 11, 22-32, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00066, September 23, 2008 DOI: 10.1215 DOI: 10. /15228517-2008 Keywords: glioma, O 6 -benzylguanine (O 6 -BG), O 6 -methylguanine-DNA methyltransferase (MGMT), polymorphism, temozolomide, U87MG G lioblastoma multiforme (GBM) is a devastating form of brain cancer in which median patient survival remains at approximately 1 year. Currently, first-line therapy for all GBM patients after surgery consists of the combination of temozolomide (TMZ) and regional fractionated radiation followed by 1 The cytotoxicity of TMZ, an oral DNA alkylating agent, results in part from DNA strand breaks caused by the addition of alkyl groups to the O 6 -position of guanine. Endogenous O 6 -methylguanine-DNA methyltransferase (MGMT) provides a major mechanism of TMZ resistance by repairing alkylated guanines, and the level of MGMT activity is correlated with cellular resistance to alkylating therapeutic agents.
TMZ alone. 1 The cytotoxicity of TMZ, an oral DNA alkylating agent, results in part from DNA strand breaks caused by the addition of alkyl groups to the O 6 -position of guanine. Endogenous O 6 -methylguanine-DNA methyltransferase (MGMT) provides a major mechanism of TMZ resistance by repairing alkylated guanines, and the level of MGMT activity is correlated with cellular resistance to alkylating therapeutic agents. 2 Following repair of a single DNA adduct, each MGMT molecule is stoichiometrically inactivated and degraded. Application of MGMT inhibitors such as O 6 -benzylguanine (O 6 -BG), an MGMT pseudosubstrate, or dose-intensive TMZ regimens are being explored clinically to increase the efficacy of TMZ by depleting tumors of MGMT. [3] [4] [5] The role of common coding-region polymorphisms in altering either the ability of MGMT to protect glioma cells from TMZ or the susceptibility to cellular depletion has not been well studied.
The biology of the common coding-region polymorphic variants of MGMT has recently been extensively reviewed. 6, 7 The three most common coding-region polymorphisms consist of the substitution of phenylalanine for leucine at amino acid position 84 (L84F) and a 100% linked pair of polymorphisms causing an isoleucine-to-valine substitution at 143 and a lysine-toarginine substitution at 178 (I143V/K178R). These are found in the general population with approximate allelic frequencies of 12%-27% (L84F) and 11%-28% (I143V/ K178R). In a study of patients with gliomas of all grades, more than 20% were found to be carriers of the L84F polymorphism. 8 Interestingly, L84F was detected more frequently in de novo GBMs than in other gliomas, suggesting that this variant may be involved in the pathogenesis of GBM. 9 Inspection of the primary amino acid sequence of MGMT shows that I143V is adjacent to the active site of MGMT, and L84F is adjacent to H85, one of the four residues that coordinates zinc binding 10 ( Fig. 1 ). Although these polymorphisms are located near active or regulatory regions of MGMT, initial in vitro studies of variants generated in bacteria have demonstrated no direct affect on the demethylating activity of MGMT. 6 In contrast, many epidemiological studies indicate that these polymorphisms are associated with an increased risk of developing a variety of cancers, including bladder, breast, prostate, and lung. 6 Accumulating evidence
indicates that these polymorphic alterations may alter more subtle functional characteristics of MGMT. For example, in vitro inactivation studies on variant MGMT species generated in bacteria demonstrate that the I143V/ K178R variant is resistant to inactivation by a variety of MGMT inhibitors, including O 6 -BG, with the effect due solely to the I143V alteration. 11, 12 Interestingly, lymphocytes isolated from healthy volunteers harboring either the L84F or I143V variant alleles had increased levels of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced chromosomal aberrations compared with wild type (WT), suggesting suboptimal repair activity of both the L84F and I143V variants. 13 The same group demonstrated that lymphocytes isolated from smokers with the L84F variation, but not I143V, were associated with increased frequencies of hypo xanthine phosphoribosyltransferase (HPRT) mutations.
14 Only one study to date has examined the relationship between these polymorphic variants and response to dacarbazine (a TMZ analogue). 15 In this retrospective melanoma study, no significant correlations were observed, although a tendency toward a lower response rate was seen for those patients harboring the I143V/K178R polymorphism.
Detailed studies to elucidate the functional effects of these polymorphic MGMT variants are required to understand the epidemiological associations between the common MGMT polymorphisms and risk of developing various cancers. Such functional studies are also valuable to predict whether the polymorphic variants affect the efficacy or toxicity of alkylating agents such as TMZ against tumor cells. In this study, we analyzed the localization and stability of the common polymorphic MGMT variants expressed in U87MG glioma cells and evaluated the effect of these alterations on the sensitivity of these cells to the cytotoxic effects of TMZ alone or combined with O 6 -BG.
Materials and Methods

Cell Culture
293T cells were maintained in Iscove's modified Dulbecco's medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Hyclone) and 100 U/ml fig. 1 . Schematic diagram of the eGfP (enhanced green fluorescent protein)-MGMT (O 6 -methylguanine-DNA methyltransferase) fusion protein amino acid sequence. The eGfP tag was linked to the N-terminus of MGMT by a five-amino-acid linker (SGLRS). The coding-region polymorphisms examined in this study are indicated for L84f (within the diamond) and for the linked pair I143V/K178R (within the circles). The residues involved in zinc-binding are underlined, and the active site residues are indicated within the rectangle. 
Retroviral Expression of eGFP-MGMT Fusion Constructs in U87MG Cells
This retroviral expression system has been previously described. 16 Briefly, 293T cells were cotransfected with 10 mg of the designated pPLCX construct containing eGFP-MGMT, 5 mg Hit-60, and 5 mg vesicular stomatitis virus glycoprotein (VSV-G) using HEPES-buffered saline and 150 mM CaCl 2 . For infection of U87MG cells, conditioned medium collected from transfected 293T cells (containing recombinant virus particles) was supplemented with 5 mg/ml Polybrene (Sigma, St. Louis, MO, USA) and added to target U87MG cells. Infected U87MG cells were selected with 0.7 mg/ml puromycin (Calbiochem, La Jolla, CA, USA). For each construct, multiple clonal cell lines were derived from the selected populations by limited dilution. Of these, two representative clones of each construct were selected for functional studies.
Western Blot Analysis of eGFP-MGMT Fusion Proteins
Cells were lysed with RIPA buffer containing 0.5% sodium dodecyl sulfate (SDS; Teknova, Hollister, CA, USA), 1% NP-40 (U.S. Biological, Swampscott, MA, USA), and 0.25% sodium deoxycholate (Sigma) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche Diagnostics, Indianapolis, IN, USA), 1 mM sodium vanadate (Fisher, Fair Lawn, NJ, USA), 1 mM sodium fluoride (Fisher), and 1 mM phenylmethanesulfonyl fluoride (Sigma). Cells were scraped and passed through a 27-5/8-gauge needle five times. The resulting lysates were spun down at maximum speed in a microcentrifuge, and the supernatants were collected. The BCA (bicinchoninic acid) Protein Assay Kit (Pierce, Rockford, IL, USA) was used to determine the total protein concentration of the resultant lysates. Total protein from U87MG eGFP-MGMT lysates (4 mg) or from U87MG eGFP lysates (1 mg) was loaded into precast Tris-HEPES-SDS gels (Pierce). Protein was transferred to nitrocellulose paper using a Transblot SD Semi-Dry Transfer Cell apparatus (Biorad, Hercules, CA, USA). Immunoblotting was performed by incubation in primary antibodies diluted in 1% milk in Tween/Tris-buffered saline using a 1:1,000 dilution of anti-GFP horseradish peroxidase (HRP; Santa Cruz Biotechnology, Santa Cruz, CA, USA; polyclonal sc-8334) or a 1:1,000 dilution of anti-MGMT (Chemicon, Temecula, CA, USA; monoclonal 16200) followed by incubation with a 1:10,000 dilution of secondary antibody conjugated to HRP (Biomeda, Foster City, CA, USA). Protein bands were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce) and exposed to film.
Quantitation of Cellular eGFP-MGMT Expression
Fluorescence plate-reader-based quantification of relative eGFP-MGMT expression level was performed as previously described. 17 Cell lysates (25 ml) were transferred to a clear 96-well plate, and fluorescence signal was quantified with a Wallac Victor2 plate reader using penicillin and 100 mg/ml streptomycin (Lonza, Walkersville, MD, USA). U87MG cells were maintained in Dulbecco's modified Eagle's medium/F12 (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 mg/ml streptomycin. All cells were grown in a 5% CO 2 humidified atmosphere. 293T and U87MG cells were obtained from Dr. P. Mischel (University of California, Los Angeles, CA, USA).
Generation of WT N-Terminus Enhanced Green Fluorescent Protein-Tagged MGMT Fusion Construct
To generate the enhanced green fluorescent protein (eGFP)-MGMT fusion construct, DNA fragments encoding MGMT and eGFP were sequentially subcloned into the pLPCX retroviral expression vector (Clontech, Mountain View, CA, USA). The pLPCX-eGFP-MGMT construct was designed to lack a stop codon following eGFP and contained a five-amino-acid "linker" segment separating eGFP and MGMT. eGFP was on the 5' end of MGMT (amino terminus of translated product) (Fig. 1) . The coding region of MGMT was amplified from human MGMT cDNA (ATCC, Manassas, VA, USA) using adaptor primers (forward primer with the HindIII site underlined and the BsrGI sites italicized: 5'-GAT CAT AAG CTT TGT ACA AGT CCG GAC TCA GGT CTA TGG ACA AGG ATT GTG AAA TGA AAC GC-3'; reverse primer with the BglII site underlined and the ClaI site italicized: 5'-GAT CAT ATC GAT AGA TCT TCA GTT TCG GCC AGC AGG CGG-3') and inserted into a HindIII-and ClaI-linearized pLPCX vector. The coding region of eGFP was amplified from the pEGFP-N1 (Clontech) vector using adaptor primers (forward primer with the HindIII site underlined: 5'-GAT CAT AAG CTT TCG CCA CCA TGG TGA GCA AGG GCG A-3'; reverse primer with the ClaI site underlined: 5'-GAT CAT ATC GAT TTA CTT GTA CAG CTC GTC CAT GCC GAG-3') and inserted into the Hind III-and Cla I-linearized pLPCX. Next, pLPCX-eGFP was digested with BsrGI to excise the eGFP gene, which was then inserted into the BsrGI-linearized pLPCX-MGMT.
Generation of Polymorphic Variant eGFP-MGMT Fusion Constructs
The combinations of the L84F, I143V, and K178R MGMT alterations were generated in pLPCX-eGFP-MGMT using the Quikchange methodology (Stratagene, La Jolla, CA, USA) with the following primer sequences: 5' L84F (5'-CCC GTG CCG GCT TTT CAC CAT CCC G-3'), 3' L84F (5'-CGG GAT GGT GAA AAG CCG GCA CGG G-3'), 5' I143V (5'-CCT GTC CCC ATC CTC GTC CCG TGC CAC AGA GTG-3'), 3' I143V (5'-CAC TCT GTG GCA CGG GAC GAG GAT GGG GAC AGG-3'), 5' K178R (5'-GGC CAC CGG TTG GGG AGG CCA GGC TTG GGA GGG-3'), and 3' K178R (5'-CCC TCC CAA GCC TGG CCT CCC CAA CCG GTG GCC-3'). Entire MGMT coding-region sequences of all constructs (including WT) were verified at the UCLA Sequencing Core Facility. 
MTT Proliferation Assay
MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assays were performed as described with some modifications. 18 Briefly, 2,000 cells were seeded in 96-well plates. After an overnight incubation, the specified concentration of TMZ (NCI/NIH Developmental Therapeutics Program, Rockville, MD, USA) and/or O 6 -BG (Sigma) in complete growth medium was added to the cells. Dimethyl sulfoxide (DMSO) solvent was added to control wells. Without replacing medium, 4 days after the addition of TMZ and/or O 6 -BG, the cells were treated with 0.5 mg/ml MTT (Sigma). After 4 h of incubation at 37ºC, the MTT was removed and the intracellular formazan crystals were solubilized with DMSO. Absorbance was quantified with a Wallac Victor2 plate reader at 535 nm and 660 nm (subtracted as reference). The results are expressed as a percentage of the absorbance measured for the untreated cultures of each corresponding clone. Three independent experiments were performed in multiples of six on two clones per construct (two experiments on one clone and one experiment on the other for each variant).
Clonogenic Cell Survival Assay
Clonogenic assays were performed as described with some modifications. 19 Briefly, 500 cells were seeded in 6-cm tissue culture dishes. Following an overnight incubation, the cells were treated with the specified concentration of TMZ and/or O 6 -BG in complete growth medium. Both compounds were initially dissolved in DMSO, and equivalent volumes of DMSO solvent were added to untreated dishes. Without replacing medium, 12 days after the addition of treatments, the cells were fixed and stained with 0.25% crystal violet in methanol. Colonies containing more than 30 cells were manually counted. The results are reported as a percentage of the colonies in untreated cultures of each corresponding clone. Three independent experiments were performed in duplicate on two clones per construct, and data are expressed as means 6 SEMs.
Cycloheximide Degradation Assay
Degradation (protein turnover) experiments were performed as previously described, with some modifications. 5 Briefly, 300,000 cells were seeded in 3.5-cm tissue culture dishes and grown overnight. Cells were treated with 50 mM cycloheximide (CHX; MP Biomedicals, Aurora, OH, USA) and, in some experiments, 5 mM bortezomib (Millenium Pharmaceuticals, Cambridge, MA, USA) or 200 mM leupeptin hemisulfate (Fisher). Because bortezomib is supplied in mannitol, control treatments included the appropriate concentration of mannitol. One h later, 25 mM O 6 -BG or an equivalent volume of its DMSO solvent was added. At indicated times following O 6 -BG application, the medium was removed and centrifuged at 6,000 rpm. The resulting pellets and the cells that adhered to the dishes were lysed with RIPA buffer supplemented as described above. Lysate (88% of the volume) was transferred to wells on a 96-well plate, and fluorescence was quantified with a Wallac Victor2 plate reader using 485-nm excitation and 535-nm emission filters. Three independent experiments were performed in duplicate on two clones for each eGFP-MGMT variant or eGFP control. Results are normalized to control treatment (e.g., CHX 1 DMSO) at the indicated time point for each cell line, except as noted. Data are expressed as means 6 SEMs.
Data Analysis
Differences were analyzed with the Student t-test. p-values < 0.05 were considered significant.
Results
Stable Expression of WT and Polymorphic Variant eGFP-MGMT Constructs in U87MG Glioma Cell Lines
To examine the subcellular localization and function of WT and MGMT coding-region polymorphic variants in glioma cells, we generated eGFP-tagged WT and mutant MGMT cDNA fusion constructs and stably expressed them in human U87MG glioma cells using the pLPCX retroviral expression system. The eGFP-tagged MGMT constructs consisted of eGFP joined to the N-terminus of MGMT by a five-amino-acid "linker" segment ( Fig.  1) . The identical eGFP-MGMT fusion protein containing a P144K mutation has previously been shown to be translated, properly localized, and functionally active. 20 We selected the U87MG glioma cell line to conduct these studies because of their low endogenous MGMT expression and high sensitivity to TMZ. 21, 22 Total cell lysates of representative stable clonal cell lines expressing eGFP or various eGFP-MGMT constructs were subjected to Western blot analysis to confirm expression using both anti-MGMT and anti-GFP antibodies. Using a monoclonal anti-MGMT antibody, a prominent band representing the full-length eGFP-MGMT fusion protein at the predicted molecular weight of eGFP-MGMT (51 kDa) was detected for the cell lines expressing WT, L84F, I143V/K178R, and L84F/I143V/ K178R along with faint apparent degradation bands ( Fig.  2A) . As expected, the 51-kDa band was not detected in uninfected U87MG cells or in U87MG cells expressing eGFP ( Fig. 2A) . Confirming the lack of appreciable endogenous MGMT expression in U87MG cells, no band was detected at the predicted molecular weight for (Fig. 2B) .
To determine the relative eGFP-MGMT expression levels of each of the clonal cell lines used in subsequent functional studies, we quantified eGFP-MGMT expression levels for two representative clonal cell lines per construct by measuring eGFP fluorescence on a plate reader and normalizing for the amount of total cellular protein measured in parallel. The WT and L84F pairs of clones were fairly evenly matched in expression, whereas the I143V/K178R and L84F/I143V/K178R pairs differed by roughly 3-fold (Fig. 2C) . Overall, differences in expression level in these pairs did not significantly affect interpretation of results of subsequent functional studies.
Polymorphic Variant eGFP-MGMT Fusion Proteins Are Properly Localized to the Nucleus
To determine the subcellular localization of the various eGFP-MGMT proteins, we performed fluorescence microscopy on live cells to visualize the distribution of eGFP fluorescence. We found that the WT eGFP-MGMT fusion protein was predominantly located in the nucleus with low-level diffuse signal in the cytoplasm (Fig.  3C) , confirming that the amino-terminal eGFP-tagged MGMT maintained nuclear localization, as found in previous studies. 20 The L84F, I143V/K178R, and L84F/ I143V/K178R eGFP-MGMT fusion proteins were also localized to the nucleus in a pattern indistinguishable from that of WT (Fig. 3D-F) , indicating that the polymorphisms individually or in combination do not affect the predominant, steady-state nuclear localization of MGMT.
Overexpression of WT and Variant eGFP-MGMT Constructs in U87MG Cells Confers Similar Resistance to TMZ Cytotoxicity
To evaluate whether L84F, I143V/K178R, or L84F/ I143V/K178R mutations alter the ability of MGMT to protect U87MG cells from the cytotoxic effects of TMZ, we first confirmed whether expression of WT eGFP-MGMT increases resistance of U87MG cells to TMZ using both MTT proliferation and clonogenic survival assays. The results of the MTT assays indicated that cells expressing WT eGFP-MGMT were significantly (p < 0.05) more resistant to the 500-and 1,000-mM TMZ concentrations than were control U87MG cells stably expressing only eGFP (Fig. 4A) . Similarly, the results of the clonogenic assays showed that cell lines expressing WT eGFP-MGMT were almost completely resistant to the effects of 100 and 500 mM TMZ and were only modestly sensitive to the effects of 1,000 mM TMZ (Fig. 4B) , whereas the colony-forming ability of eGFP-expressing cell lines was completely abolished by treatment with 100-1,000 mM TMZ (Fig. 4B) . These results confirm that amino-terminal eGFP-tagged MGMT retains repair activity and correspond with previous studies demonstrating that MGMT overexpression protects tumor cells, including glioma cells, from TMZ cytotoxicity. 19, [23] [24] [25] To determine whether introduction of polymorphic variants altered the protective ability of eGFP-MGMT against TMZ, we performed MTT and clonogenic assays on the various cell lines expressing the polymorphic variants. MTT analysis demonstrated that L84F, I143V/K178R, and L84F/I143V/K178R eGFP-MGMT conferred equal levels of protection against TMZ compared with WT eGFP-MGMT (Fig. 4A) . Cells expressing WT and variant eGFP-MGMT also displayed comparable resistance against TMZ in clonogenic assays (Fig. 4B) . These results indicate that the MGMT variants do not differ from WT in their ability to protect the cell against the cytotoxic effects of TMZ. Interestingly, inspection of individual experiments revealed no significant differences between the I143V/K178R and L84F/ I143V/K178R pairs of clones despite the 3-fold difference in expression level (data not shown). With the observation that polymorphic MGMT alteration did not alter the ability of MGMT to protect U87MG cells from TMZ, we investigated whether the polymorphic variations alter the stability of the MGMT protein. To do so, we performed CHX protein turnover experiments using a fluorescence plate reader to measure eGFP-MGMT levels remaining at various time points. We first evaluated basal degradation of the eGFP-MGMT variants by measuring eGFP-MGMT remaining after incubation in CHX only. We detected a negligible level of basal degradation of all polymorphic variants over the 8-h period of the experiment; more than 80% of signal remained after 8 h (Fig. 5A) . Because O 6 -BG, a synthetic inhibitor of MGMT, potently induces rapid degradation of MGMT, 26 we examined the stability of the various constructs upon addition of O 6 -BG. We found that treatment of cells with 25 mM O 6 -BG results in significantly (p < 0.05) greater degradation of L84F (50% signal remaining compared with untreated at 8 h) and L84F/I143V/K178R compared with WT and I143V/K178R (80% signal compared with untreated at 8 h; Fig. 5B ), indicating that O 6 -BG induces increased degradation of L84F but not I143V/K178R MGMT. These results are normalized to show the degradation induced by O 6 -BG only. The rapid turnover of the L84F/I143V/K178R protein indicated that the presence of L84F resulted in increased degradation in the context of I143V/K178R. In contrast, the addition of 1,000 mM TMZ did not stimulate significant degradation of WT or L84F eGFP-MGMT constructs at 8 h (Fig. 5C ). To confirm that the difference was not specific to the 25 mM O 6 -BG concentration, we titrated the concentration of O 6 -BG and found similar responses at O 6 -BG concentrations ranging between 25 and 100 mM (data not shown).
O 6 -BG-Stimulated Degradation of WT and L84F Is Sensitive to Proteasomal but Not Lysosomal Inhibition
Since MGMT degradation is a proteasomally dependent process, 27, 28 we sought to confirm whether the enhanced degradation of L84F is also dependent on the proteasome by treating the cell cultures with bortezomib, a clinically available dipeptide that reversibly inhibits the chymotryptic enzyme activity of the proteasome. 30 We titrated the concentration of bortezomib between 0.1 and 5 mM and observed increasing inhibition of degradation, with 5 mM resulting in complete inhibition (data not shown). Using 5 mM bortezomib, we found that O 6 -BG-induced degradation of both WT and L84F was completely inhibited (Fig. 5D) . Because of the normalization, the values above 100% represented inhibition of basal degradation by bortezomib in addition to that induced by O 6 -BG. These results indicate that both enhanced degradation of L84F stimulated by O 6 -BG and basal degradation are predominantly proteasomally dependent processes.
To determine whether O 6 -BG-induced degradation of WT and L84F is also dependent on the lysosome, we treated the cell lines with leupeptin, a lysosomal inhibitor. In contrast to the results obtained for bortezomib, the addition of 200 mM leupeptin did not inhibit O 6 -BG -induced degradation of either WT or L84F eGFP-MGMT (Fig 5D) . The addition of higher concentrations of leupeptin (200-800 mM) also had no effect on the O 6 -BG-stimulated degradation of L84F (data not shown). These results indicate that degradation of MGMT is not a lysosomally dependent process. (Fig. 6A) . In clonogenic assays, treatment with 25 mM O 6 -BG alone resulted in a small decrease in the colony-forming abilities of all the cell lines tested (Fig. 6B) .
Cells Expressing L84F Do Not Exhibit Altered
From the MTT assays, we observed that O 6 -BG renders WT and variant eGFP-MGMT-expressing cell lines as sensitive to 500-and 1,000-mM TMZ concentrations as control cells expressing eGFP (Fig. 6A) . When the clonogenic assay results were normalized to remove the effects of O 6 -BG alone, we observed that O 6 -BG renders WT and variant eGFP-MGMT-expressing cell lines as sensitive to 1,000-mM TMZ concentrations as control cells expressing eGFP (Fig. 6C ) However, both MTT and clonogenic assays indicated that the combination of O 6 -BG and TMZ sensitizes each of the WT and variant eGFP-MGMT cells equally (Fig. 6A-C) . This indistinguishable sensitivity of the WT and variant cell lines to the combination of TMZ and O 6 -BG suggests that the enhanced turnover of the L84F mutant induced by O 6 -BG does not affect its ability to protect cells from TMZ cytotoxicity.
Discussion
We established a U87MG glioma cell culture system based on overexpression of N-terminus eGFP-tagged MGMT constructs to study the effects of polymorphic alterations on TMZ-induced glioma cell cytotoxicity. We confirmed that these constructs were properly targeted and functionally active in protecting cells from TMZ cytotoxicity. Furthermore, our model system confirms that the MGMT depletional strategy using O 6 -BG can transform an MGMT-expressing cell insensitive to TMZ into a cell that is sensitive to TMZ. In this cell culture model system, all of the polymorphic variants studied behaved similarly to WT in MTT proliferation and clonogenic survival assays. While the most obvious interpretation of this data is that introduction of these amino acid variations does not result in alteration of MGMT's ability to repair TMZ-induced DNA alkylation, the possibility exists that subtle alterations are not detectable in our model system because of relatively high overexpression of the constructs. This is supported by results (data not shown) of our MTT and clonogenic experiments on I143V/K178R and L84F/I143V/K178R pairs of clones with roughly 3-fold differences in expression levels (Fig. 2C) , in which increased resistance to TMZ at Pennsylvania State University on February 21, 2013 http://neuro-oncology.oxfordjournals.org/ Downloaded from in cell lines with higher expression was not observed. This may indicate that expression level of MGMT offers increased protection against TMZ cytotoxicity up to but not beyond a certain threshold. Another possibility is that the eGFP tag somehow prevents observation of a functional change due to these polymorphic variants. Lastly, phenotypic differences of these polymorphic variants may manifest only in cell or tissue types other than gliomas.
Our major finding is that the L84F alteration shows increased degradation of MGMT in the context of O 6 -BG exposure compared with WT. An equivalent effect was observed when L84F was introduced in the context of the I143V/K178R MGMT variation, but no effect was seen upon the introduction of I143V/K178R alone. In the three-dimensional structure of MGMT, the L84F residue is relatively close to the active site, raising the possibility that this alteration affects the binding of O 6 -BG to MGMT, resulting in enhanced degradation. 7 Based on our finding that the differential degradation is sensitive to the proteasomal inhibitor bortezomib, it is also possible that the L84F variation affects the conformation of the benzylated form of MGMT. It is well established that upon DNA repair or inactivation by pseudosubstrates, MGMT undergoes a conformational change that targets it for proteasomal degradation. 6 The L84F alteration may alter this conformational change so that either the ubiquitin acceptor site is more accessible or the binding of an E3 ligase is more favorable. Threedimensional analysis of the benzylated form of L84F 
References
MGMT may demonstrate the actual structural perturbation, and generation of a series of L84 mutants may be useful to determine amino acid side-chain characteristics tolerated at that position. It will be important to determine whether tamoxifen and nitrous oxide, both recently shown to induce proteasomal degradation of MGMT, can also induce differential degradation of L84F versus WT MGMT. 26, 30 Such data may aid in understanding how these agents affect MGMT degradation.
Despite this difference in O 6 -BG -induced degradation between L84F-containing variants and WT MGMT, all of the MGMT polymorphic variants studied had nearly equivalent ability to protect U87MG cells from the cytotoxic effects of TMZ or combined TMZ/ O 6 -BG. While the failure to discover phenotypic variation could result from inherent pitfalls of our model system, the simplest interpretation of our data is that increased clearance of alkylated MGMT does not affect repair ability of MGMT. If this is indeed the case, a clue to how increased clearance of an alkylated form of a polymorphic variant of MGMT may have a biological consequence is suggested by evidence supporting the role of alkylated MGMT in suppressing estrogen receptor-a (ERa-dependent transcription via interaction with ERa). 31 This possibility has been raised by epidemiological studies showing an association between the L84F polymorphism and increased breast cancer risk. 32 The increased turnover rate of the alkylated (benzylated) L84F MGMT may result in less suppression of ERa, resulting in increased proliferation.
In conclusion, our results indicate that the L84F variant of MGMT is degraded faster in the presence of O 6 -BG, but the potential functional consequences of this difference remain to be elucidated. It may still be important to explore the roles of MGMT polymorphisms as predictive biomarkers for response to TMZ (in either conventional or depletional regimens) and how they may influence response in relation to concurrent MGMT promoter methylation. 33 Alternatively, it may be necessary to examine whether patients harboring these variants may be more susceptible to the myelotoxic effects of TMZ-based therapies independent of tumor efficacy.
